In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .
Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia.
The up date d 2003 American Urological Association ( AUA ) Guidelines for the treatment of  benign prostatic hyperplasia ( BPH ) are the culmination of an exhaustive effort predicated on scientifically accepted methods of review ing the medical literature . In this second publication of the guidelines , a multidisciplinary panel review ed a new meta- analysis of outcome data from the BPH literature from before and after 1994 . The major differences between the 2 guidelines are the changes in our underst and ing of the biology of the prostate and the introduction of new therapies . The vast majority of r and omized controlled trials , particularly with respect to minimally invasive therapies and progression of BPH , were performed after the release of the 1994 guidelines . Also , the most recent AUA panel carefully review ed unpublished data to make the guidelines as timely as possible . Studies that were subsequently published included those on the value of combination medical therapy for BPH . The panel agreed on up date d recommendations for the treatment of moderate-to-severe lower urinary tract symptoms associated with BPH , and diagnostic algorithms were revised . The durability and utility of the present guidelines should exceed that of its predecessor
In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .